tiziana-logo.png
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
June 17, 2022 16:30 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
tiziana-logo.png
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
June 10, 2022 08:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient
June 09, 2022 12:53 ET | Tiziana Life Sciences Ltd.
Zacks Small-Cap Research Note By John D. Vandermosten, CFA NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second...
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient
June 09, 2022 12:25 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug...
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient
June 09, 2022 12:04 ET | Tiziana Life Sciences Ltd.
Research Note Clinical Results for Second SPMS Patient NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second...
tiziana-logo.png
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
June 09, 2022 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
tiziana-logo.png
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
June 08, 2022 07:00 ET | Tiziana Life Sciences Ltd.
A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following three months of treatment....
tiziana-logo.png
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs
June 06, 2022 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies...
tiziana-logo.png
Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting
June 01, 2022 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
tiziana-logo.png
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
May 24, 2022 17:56 ET | Tiziana Life Sciences Ltd.
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of...